HR positive + HER-2 positive

P1, N=5, Completed, NantBioScience, Inc. | Active, not recruiting --> Completed | N=16 --> 5

Chemotherapy was the first-line regimen in 83 of 162 patients (51%), endocrine monotherapy in 55 of 162 (34%), and trastuzumab-pertuzumab-taxane or cyclin-dependent kinase 4 and 6 inhibitor-based regimens in eight of 162 (5%). 87534309); Center for Global Health at the United States-National Cancer Institute at the National Institutes of Health (contract award No. HHSN2612010000871/NO2-PC-2010-00087); Fogarty International Center, NIH, HHS; and Susan G. Komen for the Cure; in Argentina, Instituto Nacional del Cáncer (Ministry of Health), Fundación Argentina de Nanotecnología, Agencia Nacional de Promoción Científica y Tecnológica, CONICET (Ministry of Science, Technology, and Productive Innovation); Brazil, Ministério da Saúde (Ministry of Health); Chile, Instituto de Salud Pública (Public Health Institute) and Ministerio de Salud (Ministry of Health); and Mexico, Consejo Estatal de Ciencia y Tecnología de Jalisco (COECYTJAL) and Universidad de Sonora (University of Sonora).

In the PATINA trial, the addition of palbociclib to trastuzumab, pertuzumab, and endocrine therapy was associated with a clinically meaningful improvement in progression-free survival in hormone receptor-positive, HER2-positive metastatic breast cancer...More recently, HER2-CLIMB-05 demonstrated that the addition of tucatinib to dual HER2 antibody therapy significantly prolonged progression-free survival, supporting a model of sustained, multi-agent HER2 pathway suppression...Collectively, these advances support a translational framework in which antibody therapy serves as a central component of treatment strategies, with targeted partners selected according to tumor biology and prior therapy. This review summarizes the biological basis, clinical evidence, and future perspectives of antibody-driven maintenance in HER2-positive metastatic breast cancer.

A combination of ypT, ycN, and HR/HER2 status was strongly associated with ypN0 in patients with cN+ breast cancer. These findings represent a bridging study supporting risk stratification and the design of future trials evaluating axillary surgery omission.

BRD8 regulated ER-dependent and independent growth pathways, and depletion of BRD8 abolished neratinib-induced ER activation and restored drug sensitivity in resistant cells. A 3-gene BRD8 signature successfully predicted anti-HER2 therapy response in two human clinical trials. Together, these findings establish BRD8 as both a predictive biomarker for anti-HER2 response and a therapeutic target to overcome resistance in HR+/HER2+ breast cancer.

Locally advanced and metastatic thymic carcinoma remains challenging to manage, making this patient's response particularly noteworthy. Given that the therapeutic strategies for thymic tumors have remained largely unchanged in recent years, dose-dense chemotherapy may represent a promising addition to the current treatment paradigm, though further investigation is needed to evaluate its broader applicability.

While prospective validation remains limited, these technologies may help redefine surgical candidacy through biologically informed algorithms. Ultimately, the integration of surgery within a multimodal, personalized treatment strategy-guided by systemic control, tumor biology, and evolving digital tools-represents an evolving and biologically informed direction for rigorously selected patients with visceral breast cancer metastases.

In asymptomatic patients at recurrence, the first distant recurrence was detected significantly earlier using imaging modalities than using blood tests. Conclusion Symptom status at first distant breast cancer recurrence may be associated with post-recurrence survival, with asymptomatic recurrence showing more favorable outcomes.

P=N/A, N=200, Not yet recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University

The addition of palbociclib to maintenance anti-HER2 and endocrine therapies led to a significant improvement in progression-free survival over standard therapy, with increased toxic effects, mainly neutropenia. (Funded by Pfizer and others; PATINA ClinicalTrials.gov number, NCT02947685.).

P2, N=35, Not yet recruiting, Xijing Hospital